NKGen Biotech Expands Agreement Terms and Restructures COO Role

NKGen Biotech ( (NKGN) ) has provided an update.

NKGen Biotech, Inc. has amended its forward purchase agreement to increase both the prepayment shortfall and the share consideration by $250,000 and 250,000 shares, respectively. Separately, the company has also entered into a Transition Agreement with its former COO, Pierre Gagnon, who will now serve as an Advisor on an hourly basis until November 30, 2024, while continuing to vest stock options. This arrangement excludes Gagnon from company benefits and allows for at-will termination by either party.

For detailed information about NKGN stock, go to TipRanks’ Stock Analysis page.